{"entity":{"id":"nct05133882","kind":"trial","name":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","aka":[],"tldr":"A phase 1/2 trial of Clifutinib in acute myeloid leukaemia, run by Sunshine Lake Pharma Co., Ltd., now recruiting.","summary":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML is a phase 1/2 interventional study registered as NCT05133882 by Sunshine Lake Pharma Co., Ltd., with 133 participants planned, started 2022-10-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Clifutinib Besylate.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05133882","url":"https://clinicaltrials.gov/study/NCT05133882"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["clifutinib"],"companies":["sunshine-lake-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05133882","phase":"1/2","setting":"A Phase Ib/II, Multi-center, Open Clinical Trial of Crifortinib Besylate Combined With Chemotherapy in Newly-treated Adult Subjects With Acute Myeloid Leukemia","sponsor":"Sunshine Lake Pharma Co., Ltd.","enrolled":133,"outcomes":[]},"route":"/trials/nct05133882/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"clifutinib","kind":"drug","name":"Clifutinib","route":"/drugs/clifutinib/"}],"company":[{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/"}]}}